Magazine

Table: Merck's Mounting Woes


PATENT EXPIRATIONS

Patents have expired or will shortly on several big sellers, including the blockbuster hypertension drug Prinivil. When patents go, cheap generic knockoffs rapidly kill sales of the original.

VIOXX HEADACHES

Growth of the blockbuster painkiller Vioxx has slowed this year after a study raised questions about whether the drug poses a cardiovascular risk.

GAPS IN THE PIPELINE

Merck's pipeline of new drugs for the next few years is thin, so investors are anxiously awaiting the company's Dec. 11 analysts meeting. If Merck doesn't outline some potential big sellers, pressure may mount for the drugmaker to make an acquisition or sign a drug-licensing deal.


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus